Literature DB >> 35332379

Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond.

Muhsin H Younis1, Sara Malih1,2, Xiaoli Lan3,4, Mohammad Javad Rasaee5, Weibo Cai6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35332379      PMCID： PMC9074086          DOI： 10.1007/s00259-022-05766-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   10.057


× No keyword cloud information.
  19 in total

Review 1.  Synthetic multivalency for biological applications.

Authors:  Eugene Mahon; Mihail Barboiu
Journal:  Org Biomol Chem       Date:  2015-11-21       Impact factor: 3.876

2.  Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Madhav Prasad Yadav; Sanjana Ballal; Ranjit Kumar Sahoo; Sada Nand Dwivedi; Chandrasekhar Bal
Journal:  AJR Am J Roentgenol       Date:  2019-04-17       Impact factor: 3.959

3.  Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.

Authors:  Euy Sung Moon; Sanjana Ballal; Madhav Prasad Yadav; Chandrasekhar Bal; Yentl Van Rymenant; Sarah Stephan; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Roesch
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

4.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors:  Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

5.  The Latest Developments in Imaging of Fibroblast Activation Protein.

Authors:  Annette Altmann; Uwe Haberkorn; Jens Siveke
Journal:  J Nucl Med       Date:  2020-10-30       Impact factor: 10.057

Review 6.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors:  Zhibo Liu; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

7.  Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.

Authors:  Majid Assadi; Seyed Javad Rekabpour; Esmail Jafari; GhasemAli Divband; Babak Nikkholgh; Hamidreza Amini; Hassan Kamali; Sakineh Ebrahimi; Nader Shakibazad; Narges Jokar; Iraj Nabipour; Hojjat Ahmadzadehfar
Journal:  Clin Nucl Med       Date:  2021-07-14       Impact factor: 7.794

8.  Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jiao Ma; Lanying Li; Taiping Liao; Weidong Gong; Chunyin Zhang
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

9.  Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.

Authors:  Xuejun Wen; Pengfei Xu; Mengqi Shi; Jia Liu; Xinying Zeng; Yiren Zhang; Changrong Shi; Jingchao Li; Zhide Guo; Xianzhong Zhang; Pek-Lan Khong; Xiaoyuan Chen
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600
View more
  1 in total

1.  State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956-2022).

Authors:  Xiaoli Lan; Li Huo; Shuren Li; Jing Wang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07       Impact factor: 10.057
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.